MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Home・Akcijų sąrašas・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Uždarymo kaina

4.18 -3.02

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.16

Max

4.28

Pagrindiniai rodikliai
By Trading Economics
Pajamos	27M 2.5M
Pardavimai	9M 11M
Pelno marža	23.494
Darbuotojai	44
EBITDA	27M 2.6M

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	192M 832M
Ankstesnė atidarymo kaina	7.2
Ankstesnė uždarymo kaina	4.18

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

3.255 / 3.365 Palaikymas ir pasipriešinimas

Arbutus Biopharma Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-08 20:45; UTC

Uždarbis

Costco Wholesale Sales Climb in September, Early October

2025-10-08 20:12; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

TaskUs Shares Fall After Holders Reject Take-Private Deal

2025-10-08 16:39; UTC

Pagrindinės rinkos jėgos

Mining Shares Rise as Gold Prices Soar

2025-10-08 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2025-10-08 23:43; UTC

Rinkos pokalbiai

Gold Falls on Possible Profit-Taking -- Market Talk

2025-10-08 23:18; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Finance Acquisition Using Internal Funds

2025-10-08 23:17; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

2025-10-08 23:16; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

2025-10-08 21:54; UTC

Rinkos pokalbiai

Uždarbis

James Hardie Could Beat Annual Earnings Goal -- Market Talk

2025-10-08 21:30; UTC

Rinkos pokalbiai

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

2025-10-08 21:26; UTC

Rinkos pokalbiai

Uždarbis

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

2025-10-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-08 19:15; UTC

Rinkos pokalbiai

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

2025-10-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

2025-10-08 18:47; UTC

Rinkos pokalbiai

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Will Remain a Publicly Traded Co >TASK

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

2025-10-08 18:45; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

2025-10-08 18:07; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Edging Up in September -- Market Talk

2025-10-08 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-08 15:57; UTC

Rinkos pokalbiai

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

2025-10-08 15:56; UTC

Rinkos pokalbiai

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

2025-10-08 15:53; UTC

Rinkos pokalbiai

Argentine Sovereign Debt Seen as Attractive -- Market Talk

2025-10-08 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

2025-10-08 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

2025-10-08 15:43; UTC

Įsigijimai, susijungimai, perėmimai

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

2025-10-08 15:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Arbutus Biopharma Corp Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Arbutus Biopharma Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.255 / 3.365Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.